MX2021000675A - Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado). - Google Patents

Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).

Info

Publication number
MX2021000675A
MX2021000675A MX2021000675A MX2021000675A MX2021000675A MX 2021000675 A MX2021000675 A MX 2021000675A MX 2021000675 A MX2021000675 A MX 2021000675A MX 2021000675 A MX2021000675 A MX 2021000675A MX 2021000675 A MX2021000675 A MX 2021000675A
Authority
MX
Mexico
Prior art keywords
virus
aav
adeno
assay
associated virus
Prior art date
Application number
MX2021000675A
Other languages
English (en)
Inventor
Katherine A High
Federico Mingozzi
Yifeng Chen
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of MX2021000675A publication Critical patent/MX2021000675A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan vectores virales, partículas virales y métodos y usos para seleccionar, detectar, analizar y determinar cantidades de anticuerpo antiviral, o actividad de anticuerpos neutralizantes de diversas muestras. Tales vectores virales, partículas virales, y métodos y usos, son aplicables a una amplia variedad de tipos virales, tales como serotipos de lentivirus, adenovirus y virus adenoasociados (AAV). Los métodos y usos incluyen la selección de anticuerpos antivirales, tales como inmunoglobulinas antivirales seleccionadas, detectadas, analizadas y con cantidades determinadas.
MX2021000675A 2013-07-12 2016-01-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado). MX2021000675A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361845841P 2013-07-12 2013-07-12

Publications (1)

Publication Number Publication Date
MX2021000675A true MX2021000675A (es) 2021-03-25

Family

ID=52280652

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000345A MX2016000345A (es) 2013-07-12 2014-07-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).
MX2021000675A MX2021000675A (es) 2013-07-12 2016-01-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016000345A MX2016000345A (es) 2013-07-12 2014-07-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).

Country Status (12)

Country Link
US (2) US11408899B2 (es)
EP (2) EP3019620A4 (es)
JP (4) JP2016525347A (es)
KR (1) KR102445330B1 (es)
CN (2) CN105518145A (es)
AU (1) AU2014287005C1 (es)
CA (1) CA2918038C (es)
HK (1) HK1222673A1 (es)
IL (1) IL243438B (es)
MX (2) MX2016000345A (es)
RU (1) RU2705249C2 (es)
WO (1) WO2015006743A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164920A1 (en) * 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
JP6831779B2 (ja) 2015-06-23 2021-02-17 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 修飾された第ｉｘ因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用
PE20181156A1 (es) 2015-11-05 2018-07-19 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica
AU2016362477A1 (en) * 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN107828821A (zh) * 2017-11-15 2018-03-23 四川大学 一种腺相关病毒感染敏感的细胞系的构建方法及腺相关病毒中和抗体含量测定的检测方法
JP7140353B2 (ja) 2017-12-29 2022-09-22 ヘリックスミス カンパニー， リミテッド ハイブリッドｈｇｆ遺伝子が導入されたａａｖ（アデノ－関連ウイルス）ベクター
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
WO2019161365A1 (en) 2018-02-19 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
TN2020000187A1 (en) * 2018-04-05 2022-04-04 Univ Devry Val Dessonne Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
CN110846392A (zh) * 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
CN113614236A (zh) * 2018-11-16 2021-11-05 星火治疗有限公司 用于检测腺相关病毒(aav)载体转导的增强子和抑制剂和/或检测或定量抗aav结合抗体的体外测定
WO2020160373A1 (en) * 2019-01-31 2020-08-06 Precision Bioservices, Inc. Methods for detection and characterization of anti-viral vector antibodies
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
JP2023512014A (ja) 2020-01-28 2023-03-23 フリーライン セラピューティクス リミテッド ウイルスベクターに対する中和抗体力価を決定するための改善されたアッセイ
JP2023544683A (ja) * 2020-09-10 2023-10-25 ジェネトン ペプチド改変されたａａｖカプシド
CN112143712B (zh) * 2020-09-30 2022-11-01 中国科学院深圳先进技术研究院 一种重组腺相关病毒及其制备方法和在抗体检测的应用
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
CN114277090A (zh) * 2021-12-17 2022-04-05 宁波熙宁检测技术有限公司 Aav8中和抗体检测方法和检测试剂盒
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
WO2023207918A1 (en) * 2022-04-25 2023-11-02 Beijing Hanmoluojie Technology Co., Ltd. Aav capsid 3d molecular surface feature mapping
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2023220386A1 (en) * 2022-05-13 2023-11-16 The Children's Hospital Of Philadelphia Adeno-associated viral vectors for targeting brain microvasculature
CN117802161A (zh) * 2022-06-30 2024-04-02 苏州吉恒基因科技有限公司 精准重组腺相关病毒载体及其用途
WO2024098054A1 (en) * 2022-11-04 2024-05-10 The Children's Hospital Of Philadelphia Compositions and methods for b cell directed immunotherapies for anti-aav neutralizing alloantibodies
CN117285620B (zh) * 2023-11-27 2024-02-13 恺佧生物科技(上海)有限公司 抗aav9抗体及aav9滴度测定elisa试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
ATE486614T1 (de) * 1997-03-14 2010-11-15 Philadelphia Children Hospital Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
JP4025400B2 (ja) * 1997-04-16 2007-12-19 財団法人化学及血清療法研究所 新規免疫制御分子及びその製造方法
JP4060531B2 (ja) * 1998-05-28 2008-03-12 アメリカ合衆国 Ａａｖ５ベクターおよびその使用
CA2349838C (en) 1998-11-05 2011-06-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
DK1035133T3 (da) * 1999-02-17 2005-05-02 Pfizer Prod Inc Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
JP2003511037A (ja) 1999-10-01 2003-03-25 ジェノボ， インコーポレイテッド ＡＡＶｒｅｐ／ｃａｐ遺伝子を含むアデノウイルスを使用する組換えＡＡＶの産生
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
DE60117550T2 (de) * 2000-06-01 2006-12-07 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
WO2003087294A2 (de) * 2002-04-15 2003-10-23 Universitätsklinikum Hamburg-Eppendorf Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20070015238A1 (en) * 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
MXPA04012560A (es) 2002-06-13 2005-10-19 Wyeth Corp Inhibidores de la actividad genica inflamatoria y biosintesis de colesterol.
CA2738427A1 (en) * 2008-09-25 2010-04-01 Duke University A method of detecting antibodies and antibody-hiv virion complexes
LT2424991T (lt) 2009-05-02 2018-09-25 Genzyme Corporation Neurodegeneracinių sutrikimų genų terapija
CN103167896B (zh) * 2010-08-20 2015-12-16 耐克创新有限合伙公司 高尔夫球杆和高尔夫球杆头
US8202687B2 (en) 2010-10-01 2012-06-19 Panasonic Corporation Method for transporting potassium ions from front side to back side of lipid bilayer membrane
CN102576029A (zh) 2010-10-01 2012-07-11 松下电器产业株式会社 从脂质双层膜的外侧向内侧输送钾离子的方法
US8669103B2 (en) 2010-11-02 2014-03-11 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US10392632B2 (en) * 2011-02-14 2019-08-27 The Children's Hospital Of Philadelphia AAV8 vector with enhanced functional activity and methods of use thereof
CN103014064A (zh) 2011-09-22 2013-04-03 北京五加和分子医学研究所有限公司 Itr同向排列的aav载体构建及其应用
WO2013078400A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery

Also Published As

Publication number Publication date
US20220334126A1 (en) 2022-10-20
JP2016525347A (ja) 2016-08-25
WO2015006743A1 (en) 2015-01-15
CA2918038C (en) 2023-03-28
CN105518145A (zh) 2016-04-20
RU2016104614A3 (es) 2018-03-05
HK1222673A1 (zh) 2017-07-07
JP2019162109A (ja) 2019-09-26
KR102445330B1 (ko) 2022-09-19
US11408899B2 (en) 2022-08-09
IL243438A0 (en) 2016-03-31
JP2024026253A (ja) 2024-02-28
EP3019620A1 (en) 2016-05-18
EP4039813A1 (en) 2022-08-10
RU2705249C2 (ru) 2019-11-06
KR20160034332A (ko) 2016-03-29
AU2014287005A1 (en) 2016-01-28
MX2016000345A (es) 2016-06-21
JP2022037027A (ja) 2022-03-08
AU2014287005B2 (en) 2020-12-17
US20160123990A1 (en) 2016-05-05
AU2014287005C1 (en) 2021-06-03
RU2016104614A (ru) 2017-08-18
IL243438B (en) 2020-02-27
CA2918038A1 (en) 2015-01-15
EP3019620A4 (en) 2017-01-18
CN116004721A (zh) 2023-04-25

Similar Documents

Publication Publication Date Title
MX2021000675A (es) Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).
MX2021005727A (es) Ensayo in vitro para detectar potenciadores e inhibidores de la transducción de vectores virales adenoasociados (aav) y/o para detectar o cuantificar anticuerpos de unión anti-aav.
PH12018502389A1 (en) Immunochromatography analysis device for detecting zika virus
WO2014165082A3 (en) Antibodies and methods of detection
WO2014015194A3 (en) Methods for detecting and measuring aggregation
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
MX2015008045A (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano.
EA201790247A1 (ru) Платформа для очистки биспецифичных антител
EA201690731A1 (ru) Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
BR112015010758A2 (pt) Proteína de ligação de antígeno recombinante, polinucleotídeo isolado, vetor de ácido nucléico, célula do hospedeiro, e, método de detectar ou isolar uma célula que expressa estavelmente uma proteína heterodimérica
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления
ZA202002415B (en) Detection of symmetrical dimethylarginine
EA201891002A1 (ru) Иммунологический анализ для определения расщепленного высокомолекулярного кининогена
WO2011127488A3 (en) Systems and methods of processing data associated with detection and/or handling of malware
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
BR112019009765A2 (pt) anticorpo de ligação à anidrase carbônica e uso do mesmo
WO2013115410A3 (en) Anti-phospholipase d4 antibody
GB2560294A (en) Systems and methods for analyzing the characteristics and compositions of a dry cement
BR112017002622A2 (pt) métodos e sistemas para quantificação seletiva e detecção de alergênicos
BR112018013381A2 (pt) anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
WO2011116209A3 (en) Using phage epitopes to profile the immune response
WO2014039605A3 (en) Chimeric anti-dsdna/chromatin antibody
MX2016007148A (es) Metodos de ensayo de beta-glucano.